Global sites

Global sites

Unlicensed Medicines

Policy Development

Service Information

Healthcare professionals all over the world are increasingly driving demand for early access to promising new medicines for patients with unmet needs. We help pharmaceutical and biotech companies meet this growing demand with strategies to ensure early access to their medicines effectively, efficiently, and in compliance with relevant regulations.

Our Policy Development service enables pharmaceutical and biotech companies to leverage our extensive experience in the early stages of drug development to help create policies, processes and strategies that ensure a clear corporate position on early patient access to medicines (internally and externally). For example:

Developing a process to ensure continuity of treatment for patients exiting a clinical trial and consistent access for new patients with unmet medical need across different countries

Future-proofing your organisation against constant changes in the regulatory and political environment and from changing stakeholder preferences and expectations